In a British study of 115,727 patients with type 2 diabetes who became new users of oral hypoglycemic agents from 1988 through 2009, 470 incident cases of bladder cancer developed over 4.6 years of follow-up, according to an online report in the British Medical Journal.
Subjects who had ever used pioglitazone had an 83% increased risk of bladder cancer compared with nonusers, but the absolute risk remains low. The increased risk corresponds to 74 cases per 100,000 person-years compared with 73 cases per 100,000 person-years in the general U.K. population aged 65 years and older.
However, the risk rose to 88 cases per 100,000 person-years for patients who had taken pioglitazone for two years or more and 137 cases per 100,000 person-years for patients who had taken 28,000 mg or more.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.